Latest News
Oil's Geopolitical Premium Grows as Hormuz Control Dispute Intensifies
Brent crude settled at $88.52, carrying a 10.7% risk premium over fair value, as US-Iran tensions over the Strait of Hormuz persist. Energy stocks rallied, but analysts see potential downside from strong storage levels.
Ondas Rebounds 3.7% as Q4 Revenue Target Looms Large
Ondas (ONDS) shares climbed 3.7% to $9.24 on Friday, recovering part of an 8.8% post-earnings slide. The company's 2026 guidance implies a hefty $256 million Q4 revenue target, more than triple Q2 sales.
Realty Income's $1B Convertible Deal Yields $28M Annual Carry Edge
Realty Income's $1B convertible offering establishes a $28M annual carry spread, funding growth while limiting dilution. The notes convert at a 15.9% premium.
Gold's Rally Bolstered by Central Bank Buying Spree
Gold rallied nearly 10% from June lows, closing at $4,380, as central banks purchased a record 289 tonnes in Q2, signaling strong official-sector support.
Cipher Digital Surges 7.4% on Morgan Stanley's 6.3% Stake
Cipher Digital shares rose 7.4% Friday after Morgan Stanley revealed a 6.3% stake, signaling institutional interest in the company's pivot from bitcoin mining to AI data centers.
PDD Slumps 7.6% as Weak China Retail Data Raises Valuation Concerns
PDD Holdings (PDD) dropped 7.6% last week amid weak China retail data and concerns over profit quality, despite a strong cash position. July retail figures due Monday may add pressure.
China's Record Loan Drop Fuels Stimulus Debate as Demand Falters
China's new yuan loans saw a record RMB340 billion decline in July, highlighting weak demand. Markets now await activity data and the LPR decision for policy cues.
Ambev ADRs Slide 6.7% as Currency Pressure Compounds Sector Selloff
Ambev ADRs dropped 6.7% to $2.80 as the real weakened, adding to a sector-wide decline. Q2 EBITDA grew 8.9%.
Iovance Faces Make-or-Break Amtagvi Ramp as $101M Quarterly Hurdle Looms
Iovance Biotherapeutics (IOVA) fell 13.2% to $4.07 as investors weigh the steep climb to $101 million in quarterly Amtagvi revenue needed to hit 2026 guidance.